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IranAbstract Objectives: Treatment outcome of Tuberculosis (TB), as a key determinant to evaluate
the effectiveness of TB control program, remains a public health challenge in many developed and
developing countries. This study aimed to assess treatment outcomes of new smear-positive pul-
monary tuberculosis (PTB).
Methods: This retrospective cross-sectional study was conducted on 510 registered new PTB
patients in Hamadan province, Iran during 2005–13. The data were extracted from the National
TB Program (NTP). The main outcome was treatment success. The results of evaluation of the asso-
ciated factors with successful treatment were presented as Odds Ratios (OR), and bootstrap method
was used to obtain 95% Confidence Interval (95% CI). All statistical analysis was performed at 0.05
significant levels using the Stata 12 (Stata Corp, College Station, TX, USA).
Results: Overall, successful treatment outcome was 83.1%, and 9.4% of the patients died during
the study period. In univariate logistic regression, only hospitalization history was associated withz, Iran.
826 S. Khazaei et al.successful treatment (OR = 2.02, 95% CI: 1.25, 3.24). After adjustment for age, weight, and
delayed diagnosis, the factors associated with successful treatment were gender and having HIV risk
factors and hospitalization history.
Conclusion: Treatment success rate in our study was 83.1%, which is slightly lower than the suc-
cess target set by World Health Organization (WHO). Key determinants of poor treatment success
rate, such as male gender, and not having hospitalization history during the treatment period,
should be considered in efforts aimed to improve the treatment outcome in the management of TB.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Table 1 Treatment outcomes for new PTB patients according
to WHO’s guideline [12].
Outcome Definition
Cured A pulmonary TB patient with bacteriological
confirmed TB at the beginning of treatment who
was smear- or culture-negative in the last month
of treatment and on at least one previous
occasion
Treatment
completed
A TB patient who completed treatment without
evidence of failure BUT with no record to show
that sputum smear or culture results in the last
month of treatment and on at least one previous
occasion were negative, either because tests were
not done or because results are unavailable
Treatment
failed
A TB patient whose sputum smear or culture is
positive at month 5 or later during treatment
Died A TB patient who dies for any reason before
starting or during the course of treatment
Lost to follow-
up
A TB patient who did not start treatment or
whose treatment was interrupted for 2
consecutive months or more
Not evaluated A TB patient for whom no treatment outcome is
assigned. This includes cases ‘‘transferred out” to
another treatment unit as well as cases for whom
the treatment outcome is unknown to the
reporting unit
Treatment
success
The sum of cured and treatment completed
PTB: positive pulmonary tuberculosis.Introduction
Tuberculosis (TB) is a public health problem and the leading
cause of death with an annual incidence rate of about 8.6 mil-
lion cases. Additionally, 1.3 million people have been esti-
mated to die due to the disease every year [1]. The burden of
TB is the highest in Asia (59%) and Africa (26%) [2]. Besides,
the case fatality rate has exceeded 50% in some African coun-
tries where HIV infection rates are high [3]. In Iran, the inci-
dence rate of TB was 14.4 per 100,000 people in 2012 and
about 50% of them was smear-positive pulmonary tuberculo-
sis (PTB) [4].
In TB control program, it is important to achieve and sus-
tain acceptable levels of treatment success among all TB
patients. Therefore, treatment success is measured by a stan-
dardized process of treatment outcome monitoring [5]. In fact,
treatment ‘‘success’’ has been measured by the number of
patients being ‘‘cured’’ and those having their ‘‘treatment com-
pleted’’ [6]. Successful treatment of PTB has obvious benefits to
both individual patients and the community. Hence, it can have
an immediate impact on TB prevalence and mortality rates. On
the other hand, a 95% reduction in TB-related deaths and a
90% reduction in TB incidence rate are the overall target of
the strategy to end the global TB epidemic by 2035 [7].
The treatment success rate among all new TB cases was
86% globally [7]. This proportion varied from 75% in the
European Region to 92% in the Western Pacific Region
among the six World Health Organization (WHO) regions
[7]. A systematic review in European Union countries also
showed that treatment success rate varied from 60% to 87%
[8]. Some factors, such as high prevalence of HIV/AIDS, high
prevalence of drug resistance, poor quality of medical services,
and aging, affect the treatment success [9,10].
Monitoring and assessing the treatment outcome of TB is
essential in order to evaluate the effectiveness of interventions.
Therefore, this study aims to assess the treatment outcomes of
all PTB patients over a 9-year period by reviewing the regis-
tered cases in Hamadan province, Iran. This will enable us
to ascertain the effectiveness of our treatment program and
determine the risk factors of unsuccessful treatment outcome
and longer treatment duration.
Methods
This cross-sectional study was performed on TB patients in
Hamadan province, Iran using the surveillance database. All
the registered smear-positive TB patients in all parts of the
province (510 patients) from 2005 to 2013 were included inthe study. The inclusion criteria of the study were (a) being a
new case of TB and (b) living in Hamadan province. For diag-
nosis of sputum smear-positive TB, a case must meet one of
the following criteria: (a) two positive sputum smears by
microscopy, (b) one positive sputum smear and one positive
sputum culture, and (c) one positive sputum smear with typical
pathology of active TB on chest X-ray [11]. The data were
extracted from the National TB Program (NTP) using a check-
list of items, including gender, age, weight, delayed diagnosis
(the time interval between the onset of TB symptoms to diag-
nosis), residency status (urban/rural), HIV status, hospitaliza-
tion history during the treatment period, laboratory result
before treatment (1–9 Basil, 1+, 2+, 3+), and treatment out-
comes of new PTB patients based on WHO’s definition
(Table 1) [12].
To analyze the data, the categories ‘‘cured” and ‘‘treatment
completed” were combined as treatment success (the main out-
come). The TB patients with other outcomes (treatment failed,
Table 3 Treatment outcomes in new PTB patients in
Hamadan, Iran.
Number Percent
Registered TB on treatment 510 100
Treatment success 424 83.1
Death 48 9.4
Transfer out 5 1.0
Failure 20 3.9
Absent 13 2.6
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unsuccessful treatment.
For data analysis, descriptive statistics, including frequency
tables and percentage, were used to describe the study vari-
ables. In addition, chi-square test was used to compare the
study groups. To determine the effect of predictors on treat-
ment success, crude and adjusted Odds Ratios (OR) with
95% Confidence Interval (95% CI) were reported using logis-
tic regression. In this study, bootstrap technique with 1000
replications was used to obtain 95% CI. In adjusted model,
each predictor was entered into the model together with age,
weight, and delayed diagnosis. To assess the effect of age, only
weight and delayed diagnosis were entered into the model. All
the analytical operations were performed using the Stata soft-
ware, version 12 (Stata Corp, College Station, TX, USA) and
P< 0.05 was considered to be statistically significant.
Results
During the study period (2005–13), a total of 510 PTB patients
were included in the study. The mean age of the study patients
was 56.8 (SD ± 21.4) years, 52.2% were male, and 39.6%
lived in rural areas. In addition, hospitalization history during
the treatment period was present in 52.7% of the patients and
2.7% were HIV-positive. Distribution of the demographic
characteristics of the new PTB patients is shown in Table 2.
Overall, the mean treatment success of all the registered
PTB patients was 83.1% during 2005–13. The summary of
the treatment outcomes of all the new PTB patients during
2005–13 is presented in Table 3.Table 2 Distribution of the demographic characteristics of
the new PTB patients in Hamadan province, Iran from 2005 to
2013.
Variable Successful Unsuccessful Total P-value
No. % No. %
Gender 0.146
Male 215 80.8 51 19.2 266
Female 209 85.7 35 14.3 244
Age group (year) 0.211
<30 75 87.2 11 12.8 86
31–60 136 85.5 23 14.5 159
>61 213 80.4 52 19.6 265
Location 0.639
Urban 258 83.8 50 16.2 308
Rural 166 82.2 36 17.8 202
Having HIV risk
factors
0.155
No 390 83.9 75 16.1 465
Yes 34 75.5 11 24.5 45
Having TB risk
factors
0.248
No 351 83.9 67 16.1 418
Yes 73 79.4 19 20.6 92
HIV status 0.235
No 414 83.5 82 16.5 496
Yes 10 71.4 4 28.6 14
Hospitalization
history
0.003
No 188 78.0 53 22.0 241
Yes 236 87.7 33 12.3 269In univariate logistic regression, only hospitalization his-
tory during the treatment period was associated with successful
treatment (OR = 2.02, 95% CI: 1.25, 3.24). After adjustment
for the possible confounding factors, such as age, weight, and
delayed diagnosis (Table 4), successful treatment was found to
be significantly associated with male gender (OR = 0.54, 95%
CI: 0.31, 0.94), having HIV risk factors (OR = 0.36, 95% CI:
0.15, 0.84), and having hospitalization history during the treat-
ment period (OR= 1.89, 95% CI: 1.15, 3.12). The association
between successful treatment and age, location, HIV status,
and having TB risk factors was not significant (Table 4).
Discussion
This study aimed to assess the treatment outcomes of PTB
patients over a 9-year period and revealed the overall treat-
ment success rate to be 83.1%, which is slightly lower than
the WHO’s target of 85% [1]. The proportion of treatment suc-
cess in this study was also lower than that reported in the pre-
vious studies in different parts of Iran [2,13]. However, it was
higher compared to the proportion reported in other countries
[5,6]. This difference might be explained by several different
factors, such as the study sample size, the proportion of vari-
ables including rural residency, old age, and male gender, the
study period, HIV status of TB patients, and the quality of
health services. As a result, the factors associated with poor
treatment outcome are likely to be different among the world
countries and also within a country. Over 90% treatment suc-
cess rate by 2025 is one of the main goals of Iran’s Ministry of
Health and Medical Education (MOHME) [14]. Accordingly,
information about the factors associated with treatment out-
come may help policymakers to ensure a successful TB control
program and also to achieve the target of treatment success.
In the present study, the results of univariate logistic regres-
sion indicated no significant relationship between gender and
treatment outcome. However, after controlling for weight,
age, and delayed diagnosis, the results demonstrated that
unsuccessful treatment was more likely among males com-
pared to females. The higher proportion of unsuccessful treat-
ment outcome in males might be related to their high-risk
behaviors, such as substance and alcohol abuse, and more
infection with HIV. In this regard, the results showed 92.8%
HIV co-infection among male patients. A study in Iran also
revealed that sex was independently associated with TB/HIV
co-infection [15]. Although we have no information about sub-
stance and alcohol abuse, Jakubowiak et al. [16] and John-
stone et al. [4] found that alcohol consumption was related
to an increased risk of treatment failure. Our finding was in
agreement with those of other studies [3–5], indicating a direct
Table 4 Logistic regression analysis of the potentially associated factors with treatment success.
Crude model Adjusted model*
OR 95% CI P-value OR 95% CI P-value
Sex
Female 1.00 – – 1.00 – –
Male 0.71 (0.43, 1.15) 0.164 0.54 (0.31, 0.94) 0.029
Age (year)
<60 1.00 – – 1.00 – –
>61 0.66 (0.41, 1.05) 0.08 0.67 (0.40, 1.31) 0.131
Location
Urban 1.00 – – 1.00 – –
Rural 0.89 (0.56, 1.43) 0.64 0.93 (0.56, 1.54) 0.766
HIV status
No 1.00 – – 1.00 – –
Yes 0.50 (0.15, 1.65) 0.253 0.31 (0.08, 1.28) 0.106
Having HIV risk factors
No
Yes 0.59 (0.29, 1.21) 0.152 0.36 (0.15, 0.84) 0.018
Having TB risk factors
No 1.00 – – 1.00 – –
Yes 0.73 (0.41, 1.32) 0.302 0.69 (0.36, 1.31) 0.251
Hospitalization history
No 1.00 – – 1.00 – –
Yes 2.02 (1.25, 3.24) 0.004 1.89 (1.15, 3.12) 0.012
The bold indicates P-value < 0.05.
* Adjusted for age, weight, and delayed diagnosis (for age group, only weight and delayed diagnosis were adjusted).
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ment outcome. However, some studies have shown no varia-
tion by sex in the treatment outcome [11]. Other possible
reasons for this gender disparity might be social, environmen-
tal, and health-related factors [17,18] which might be the
causes of the high prevalence rate of multidrug-resistant TB
(MDR-TB) among men [19].
We also found the prevalence rate of HIV co-infection of
2.7% among the TB patients. Besides, no significant relation-
ship was observed between HIV co-infection and treatment
outcome. This might be due to the small sample of TB patients
with HIV co-infection. On the other hand, previous studies
have found that HIV co-infection was an independent predic-
tor of unsuccessful treatment outcome [20,21]. The prevalence
of TB/HIV co-infection varied among countries; 23.5% in
China [22], 42% in Southern Africa [23], 30% in Brazil [24],
and 2.4% in Iran [25]. Although the prevalence rate of HIV
co-infection in our study was slightly higher than the national
average [25,26], it was very low compared to other regions.
This finding might be justified by individuals’ low demand
for HIV testing [27]. On the other hand, the results of adjusted
logistic regression disclosed that having HIV risk factors, such
as unprotected sex, was a predictor of unsuccessful treatment.
Age is an important factor in TB and its related outcomes
[11,18,28,29]. Based on both univariate and adjusted logistic
regression in the current study, no significant association was
found between age and treatment outcome. This is inconsistent
with the findings of other studies in Asia [11], USA [28], and
Africa [30]. The higher rate of unsuccessful treatment observed
among elderly patients may be due to complication with other
diseases like diabetes mellitus, hypertension, and cardiovascu-
lar diseases or some high-risk behaviors, such as smoking and
alcohol abuse, in this age group. Accordingly, assessment and
recording of co-morbidities and high-risk behaviors might helpphysicians and health workers improve the treatment outcome
in the management of TB.
In our study, the TB patients with hospitalization history
during the treatment period were approximately 2 times more
likely to have successful treatment in both univariate and
adjusted models. We found no similar studies in this regard
for comparison of the results. The directly observed treatment
of short course (DOTS) strategy as a cost-effective strategy
done by healthcare workers could justify this finding.
There was no significant association between place of resi-
dency and treatment outcome. There are some reasons justifying
this phenomenon including a high coverage of health insurance
system in Iran even in rural areas, implementation of DOTS
strategy and implementation of family physician in rural area
which might help to improve the diagnosis and treatment out-
come of the patients. There are conflicting results in this regard.
For example, a study conducted in Pakistan revealed that poor
outcome of TB treatment was associated with living in rural
areas [31]. Another study in Ethiopia reported that the treat-
ment success was higher in rural areas [32].
Our study had some limitations. We used registry-based
data for analysis. Accordingly, we could not directly investi-
gate the TB patients’ information about some variables, such
as HIV status, HIV risk factors, and hospitalization history.
This might have caused information bias, leading to underesti-
mation of the variables’ statuses.Conclusion
The treatment success rate in our study was 83.1%, which is
slightly lower than the success target set by WHO. The key
determinants of poor treatment success rate, such as male
gender, and not having hospitalization history during the
Treatment outcome of tuberculosis in Hamadan 829treatment period, should be considered in efforts aimed to
improve the treatment outcome in the management of TB.
Moreover, future epidemiological studies are required to
identify the key factors associated with treatment success to
prevent TB resistance to treatment and decrease morbidity,
mortality, and period of infection.Authors’ contributions
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